Cargando…

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

INTRODUCTION: Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rauch, Thomas, Graefe-Mody, Ulrike, Deacon, Carolyn F., Ring, Arne, Holst, Jens J., Woerle, Hans-Juergen, Dugi, Klaus A., Heise, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare Communications 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508116/ https://www.ncbi.nlm.nih.gov/pubmed/22986920 http://dx.doi.org/10.1007/s13300-012-0010-y

Ejemplares similares

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
por: Zimdahl, Heike, et al.
Publicado: (2014)

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
por: Retlich, Silke, et al.
Publicado: (2015)

Incorrect description of mode of excretion of linagliptin
por: Woerle, Hans-Juergen, et al.
Publicado: (2010)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
por: Yoo, Soyeon, et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2013)

Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo
por: Horie, Yoshiharu, et al.
Publicado: (2009)

Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes
por: Sarashina, Akiko, et al.
Publicado: (2016)

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
por: Johansen, Odd Erik, et al.
Publicado: (2012)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
por: Capozzi, Megan E, et al.
Publicado: (2018)

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial
por: Chen, Yuhong, et al.
Publicado: (2015)

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials
por: Davidson, Jaime A, et al.
Publicado: (2014)

Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
por: Ceccarelli, Elena, et al.
Publicado: (2013)

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
por: Groop, Per-Henrik, et al.
Publicado: (2013)

Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus
por: Yeow, Toh Peng, et al.
Publicado: (2017)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
por: Singh, Awadhesh Kumar
Publicado: (2015)

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
por: von Eynatten, Maximilian, et al.
Publicado: (2013)

The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes
por: Woerle, Hans Juergen, et al.
Publicado: (2012)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

The Links of Ghrelin to Incretins, Insulin, Glucagon, and Leptin After Bariatric Surgery
por: Skuratovskaia, Daria, et al.
Publicado: (2021)

Incretin hormones and the satiation signal
por: Holst, J J
Publicado: (2013)

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
por: Hare, Kristine J., et al.
Publicado: (2010)

The Role of Incretins on Insulin Function and Glucose Homeostasis
por: Holst, Jens Juul, et al.
Publicado: (2021)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases
por: Salvatore, Teresa, et al.
Publicado: (2019)

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
por: Boer, Geke Aline, et al.
Publicado: (2020)

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study
por: Yki-Järvinen, Hannele, et al.
Publicado: (2013)

Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone
por: Davidson, Jaime A.
Publicado: (2013)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
por: Kanasaki, Keizo, et al.
Publicado: (2019)

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(®))
por: Marx, Nikolaus, et al.
Publicado: (2015)

Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes
por: Menge, Björn A., et al.
Publicado: (2011)

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
por: Groop, P-H, et al.
Publicado: (2014)

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
por: McGill, Janet B., et al.
Publicado: (2013)

Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial
por: Wu, Wenjun, et al.
Publicado: (2015)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus
por: Kim, Mi-Hyun, et al.
Publicado: (2010)

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses
por: Engelbrechtsen, Line, et al.
Publicado: (2018)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5gq10d21icj8uko62d1rtgt8r4